Table 3.

Risk of COVID-19 and its complications among fully vaccinated patients with AD compared to non-vaccinated patients with AD

	COVID-19 infection		COVID-19-associated hospitalization		COVID-19-associated mortality
	Fully vaccinated until February/2021 (N = 42,433)	Non-vaccinated until February/2021 (N = 19,100)	Fully vaccinated until February/2021 (N = 42,433)	Non-vaccinated until February/2021 (N = 19,100)	Fully vaccinated until February/2021 (N = 42,433)	Non-vaccinated until February/2021 (N = 19,100)
Follow-up time, PY	16,714.6	6,116.4	16,744.8	6,163.1	16,747.0	6,172.3
Median follow-up time, months (range)	4.8 (0.2–5.5)	3.9 (0.2–3.9)	4.8 (0.2–5.5)	3.9 (0.2–3.9)	4.8 (0.7–5.5)	3.9 (0.1–3.9)
Number of events	104	210	9	41	2	9
Incidence rate/1000 PY (95% CI)	6.2 (5.1–7.5)	34.3 (29.9–39.2)	0.5 (0.3–1.0)	6.7 (4.8–8.9)	0.1 (0.02–0.4)	1.5 (0.7–2.7)
Unadjusted HR (95% CI) [p value]	0.21 (0.17–0.27) [< 0.001]	Reference	0.14 (0.06–0.28) [< 0.001]	Reference	0.10 (0.02–0.46) [0.003]	Reference
Age-adjusted and sex-adjusted HR (95% CI) [p value]	0.19 (0.15–0.24) [< 0.001]	Reference	0.08 (0.04–0.17) [< 0.001]	Reference	0.04 (0.01–0.17) [< 0.001]	Reference
Fully adjusted HR (95% CI) [p value]a	0.20 (0.16–0.26) [< 0.001]	Reference	0.08 (0.04–0.18) [< 0.001]	Reference	0.04 (0.01–0.20) [< 0.001]	Reference

Bold: significant values

AD atopic dermatitis, CI confidence interval, COVID-19 coronavirus disease 2019, HR hazard ratio, NA non-applicable, PY person-years

^aMulti-variate logistic regression model adjusting for age, sex, ethnicity, cardiovascular diseases, metabolic syndrome, chronic obstructive pulmonary disorder, chronic renal failure, malignancy, and smoking